Cannabidiol (CBD) is scientifically validated for the treatment of certain types of convulsions, specifically in rare, severe forms of epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome. Multiple high-quality randomized controlled trials have demonstrated that pharmaceutical-grade CBD, such as Epidiolex, can significantly reduce the frequency of seizures in patients with these conditions. The U.S. Food and Drug Administration (FDA) approved Epidiolex in 2018 after reviewing clinical trial data showing that CBD was effective as an adjunct therapy for seizure reduction in these syndromes, which are often resistant to other antiepileptic drugs.

The mechanism by which CBD exerts its anticonvulsant effect is not fully understood but is thought to involve modulation of the endocannabinoid system, inhibition of excitatory neurotransmitter release, and possible effects on calcium channels and other molecular targets. Importantly, the efficacy and safety of CBD for seizure disorders are supported by rigorous peer-reviewed studies, systematic reviews, and meta-analyses. While CBD is not a cure for epilepsy, its use represents a significant advance in the management of otherwise intractable convulsive disorders.

It should be noted that the evidence for over-the-counter or non-pharmaceutical CBD products is lacking, and only standardized, prescription formulations have demonstrated efficacy and safety in clinical trials.